UCLA researchers recently developed a simple, low-cost blood test called MethylScan that detects multiple cancers and organ abnormalities simultaneously by analyzing circulating DNA fragments.
This innovative diagnostic tool identifies disease signals within the bloodstream, offering a more affordable way to catch life-threatening conditions before they reach advanced stages. Consequently, this advancement could shift the focus of modern medicine toward highly effective, early-stage interventions rather than late-stage treatments.
The Power of Early Intervention
Dr. Jasmine Zhou emphasizes that catchng cancer at stage one leads to dramatically better outcomes compared to a stage four diagnosis. Because survival rates increase significantly with early detection, a universal screening tool like MethylScan provides an essential advantage for long-term patient health. This test specifically targets cell-free DNA (cfDNA), which are genetic fragments released into the blood whenever cells naturally die.
How MethylScan Decodes Health via DNA
Every day, approximately 50 to 70 billion cells in the human body die and release their genetic material into the circulatory system. This means that the blood already contains comprehensive information about the health status of every organ in the body. While traditional liquid biopsies often look for rare genetic mutations, MethylScan focuses on DNA methylation, which are chemical markers regulating gene activity. Furthermore, these methylation patterns shift noticeably when cells become cancerous, providing a very informative signal for clinicians.
Overcoming the Noise in Blood Samples
A major challenge in blood-based testing is that 80% to 90% of circulating DNA comes from normal, healthy blood cells. To solve this, the UCLA team developed a method using specialized enzymes to selectively remove background noise from healthy cells.
By enriching the sample for methylated DNA from solid organs, they can maintain high sensitivity while reducing the need for expensive sequencing. In addition, this efficiency could lower the cost of a single test to under $20.
Proven Results in Clinical Trials
To validate the test, researchers analyzed blood samples from 1,061 individuals, including patients with lung, liver, ovarian, and stomach cancers. The study also included participants with various liver diseases, such as hepatitis and metabolic disorders, alongside healthy control subjects.
Machine learning algorithms then interpreted the complex data to identify specific disease origins with high accuracy. Ultimately, this research represents a major step toward making comprehensive health monitoring accessible to everyone.
Proven Accuracy in Cancer Detection
The clinical data shows that MethylScan maintains a high level of accuracy while scanning for multiple types of cancer across various stages. Specifically, at a 98% specificity rate, the test successfully identifies approximately 63% of all cancers and 55% of early-stage cases. Furthermore, the test is highly effective for high-risk patients, detecting nearly 80% of liver cancer cases with a specificity above 90%.
Consequently, this performance indicates a false positive rate of below 10%, which is vital for reducing unnecessary patient anxiety during screening.
Identifying the Origin of Disease
Beyond mere detection, this technology offers clinicians deep insights into where a disease originates within the human body’s complex systems. Identifying the “tissue of origin” is a crucial step because it directs doctors toward the specific organ requiring further diagnostic imaging. MethylScan effectively functions as a system-wide health monitor, detecting organ stress in the liver or lungs before visible symptoms even appear.
Revolutionising Liver Health Management
Additionally, the test distinguishes between different liver conditions, such as viral hepatitis and metabolic-associated liver disease, with an 85% accuracy rate. This breakthrough suggests that MethylScan could eventually reduce the medical community’s reliance on invasive and painful liver biopsies. While researchers still require larger prospective studies for real-world confirmation, this advancement represents a major leap toward universal disease detection.
Analysis: A Shift in Diagnostic Economics
The primary impact of MethylScan lies in its potential to democratize high-end medical diagnostics through significant cost reduction. Traditional mutation-based tests require deep sequencing and expensive technology, which often limits their use to wealthy populations or specialized clinics. By utilizing methylation markers and enzymatic noise reduction, MethylScan makes frequent, population-wide screening a realistic possibility. Therefore, this technology could reduce the global burden of cancer by making “detect and treat” the standard of care.
Q&A: Everything You Need to Know About MethylScan
Q: How does MethylScan differ from a standard liquid biopsy?
A: Most liquid biopsies search for specific genetic mutations, whereas MethylScan analyzes chemical methylation patterns that reflect the overall health of tissues.
Q: Can this test detect diseases other than cancer?
A: Yes, the test successfully identified liver diseases like hepatitis and alcohol-related liver disease, as well as benign lung nodules.
Q: Is the test currently available for the general public?
A: The research was recently published in the Proceedings of the National Academy of Sciences, and further clinical implementation is expected following these successful trials.
Frequently Asked Questions (FAQ)
What is the estimated cost of a MethylScan test?
If sequencing costs continue to fall, the researchers estimate the data required for a sample could cost under $20.
Which cancers were included in the UCLA study?
The study evaluated patients with liver, lung, ovarian, and stomach cancers to test the diagnostic accuracy of the platform.
Why is DNA methylation a better signal than mutations?
Methylation patterns are highly specific to different tissue types and provide a clearer picture of the current health status of an organ.
How many people participated in the trial?
The researchers analyzed blood samples from a diverse group of 1,061 individuals to ensure the machine learning models were robust.
